Driving Titan International enjoys over 50% stock bump on institutional investor attention Several major investors have also recently adjusted their holdings in Titan International Joseph MortonDecember 9, 2024
Medical and Pharmaceutical Janux Therapeutics soars on clinical trial data for prostate cancer treatment candidate For 63 per cent of patients, the cancer was either reduced or kept from worsening Joseph MortonDecember 3, 2024
Health & Wellness Poseida Therapeutics shares skyrocket on acquisition from pharma-giant Roche Poseida's proprietary non-viral gene engineering technology has delivered promising early clinical results Joseph MortonNovember 26, 2024
News For-profit prison company shares skyrocket on Trump win Investors are betting on stricter immigration policies under a potential Trump administration Joseph MortonNovember 6, 2024
Bitcoin Bit Digital expands into high performance computing with Enovum acquisition This development comes as part of Bit Digital's broader strategy to diversify and strengthen its market position beyond bitcoin mining Joseph MortonOctober 15, 2024
Health & Wellness The five front war against cancer: A mugglehead roundup The American Cancer Society says one in four men and one in five women will develop cancer at some point in their lives Joseph MortonOctober 11, 2024
Technology Red Cat Holdings shares jump on Customs and Border Protection drone deal The market for drones, especially in military, defense, and commercial applications, is substantial and growing rapidly Joseph MortonOctober 8, 2024
Lithium Piedmont Lithium shares jump on Ghana environmental permit Despite potential quarterly earnings losses, Piedmont’s strategic moves suggest solid operational progress Joseph MortonOctober 2, 2024
Crypto/Blockchain PayPal lets merchants actually do business with cryptocurrency U.S. merchants can now transfer cryptocurrency externally on-chain to third-party eligible wallets through PayPal Joseph MortonSeptember 27, 2024
Health & Wellness Relay Therapeutics shares soar on positive results for breast cancer treatment Several analysts upgraded their price targets for Relay Therapeutics based on the release Joseph MortonSeptember 9, 2024